Next Article in Journal / Special Issue
Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ)
Previous Article in Journal
Behavior Assessment in Children Following Hospital-Based General Anesthesia versus Office-Based General Anesthesia
Previous Article in Special Issue
Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw
Article Menu

Export Article

Open AccessReview
Dent. J. 2016, 4(3), 28; doi:10.3390/dj4030028

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned

1
Department of Urology, University of Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
2
Department of Maxillofacial Surgery, University of Mainz, 55131 Mainz, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Patrick R. Schmidlin
Received: 27 May 2016 / Revised: 30 July 2016 / Accepted: 17 August 2016 / Published: 19 August 2016
(This article belongs to the Special Issue New Cancer and Osteoporosis Therapies and Osteocrosis of the Jaws)
View Full-Text   |   Download PDF [195 KB, uploaded 19 August 2016]

Abstract

Nine out of ten metastatic prostate cancer (PCa) patients will develop osseous metastases. Of these, every second will suffer from skeletal-related events (SRE). SRE are associated with an increased risk for death, which is markedly increased in the presence of pathological fracture. Moreover, health insurance costs nearly double in the presence of SRE. Zoledronic acid and denosumab are both approved drugs for the prevention or delay of SRE in castration-resistant prostate cancer (CRPC) patients with osseous metastases. However, long-term treatment with one of these two drugs is associated with the development of medication-related osteonecrosis of the jaw (MRONJ). Routine inspections of the oral cavity before and during treatment are mandatory in these patients. Regarding imaging techniques, bone scintigraphy seems to be a promising tool to detect early stage MRONJ. Zoledronic acid does not reduce the incidence of SRE in hormone-sensitive PCa. First data shows 3-monthly application of zoledronic acid to be equi-effective to monthly application. View Full-Text
Keywords: zoledronic acid; denosumab; prostate cancer; osteonecrosis zoledronic acid; denosumab; prostate cancer; osteonecrosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Thomas, C.; Bartsch, G.; Walter, C.; Borgmann, H.; Brandt, M.P.; Höfner, T.; Haferkamp, A.; Tsaur, I. Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned. Dent. J. 2016, 4, 28.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Dent. J. EISSN 2304-6767 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top